Soligenix Past Earnings Performance

Past criteria checks 0/6

Soligenix has been growing earnings at an average annual rate of 11.4%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 45.9% per year.

Key information

11.4%

Earnings growth rate

38.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-45.9%
Return on equity-119.6%
Net Margin-1,949.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Sep 06

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Sep 06
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Aug 12

Soligenix, SERB Pharma team up to develop therapy for ricin poisoning

Jul 25

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Apr 22
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Jan 03
Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17
Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30
Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08
Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16
What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Revenue & Expenses Breakdown

How Soligenix makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:SNGX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-753
30 Jun 240-753
31 Mar 241-743
31 Dec 231-643
30 Sep 231-855
30 Jun 231-1056
31 Mar 231-1057
31 Dec 221-1478
30 Sep 221-1578
30 Jun 221-1579
31 Mar 221-1579
31 Dec 211-1358
30 Sep 211-1359
30 Jun 211-1258
31 Mar 212-1248
31 Dec 202-18415
30 Sep 203-15313
30 Jun 203-16314
31 Mar 204-15314
31 Dec 195-938
30 Sep 195-1038
30 Jun 195-937
31 Mar 195-837
31 Dec 185-937
30 Sep 186-836
30 Jun 186-735
31 Mar 185-836
31 Dec 175-736
30 Sep 176-534
30 Jun 177-635
31 Mar 179-434
31 Dec 1610-334
30 Sep 1612-545
30 Jun 1613-145
31 Mar 1611-446
31 Dec 159-845
30 Sep 158-435
30 Jun 157-1135
31 Mar 157-835
31 Dec 147-735
30 Sep 146-834
30 Jun 144-1034
31 Mar 143-1235
31 Dec 133-1035

Quality Earnings: SNGX is currently unprofitable.

Growing Profit Margin: SNGX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SNGX is unprofitable, but has reduced losses over the past 5 years at a rate of 11.4% per year.

Accelerating Growth: Unable to compare SNGX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SNGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: SNGX has a negative Return on Equity (-119.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 19:35
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Soligenix, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerAegis Capital Corporation
James MolloyAlliance Global Partners
Jonathan AschoffBrean Capital